GCN | Jotup

Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results

Retrieved on:

Thursday, March 28, 2024

APLM, NSCLC, New Drug Application, Patient, NDA, Lung cancer, MET, GCN, FDA, Met, Food, Pharmaceutical industry

ET

Key Points:

ET
FOSTER CITY, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late- stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced financial results for the full year ended December 31, 2023, and highlighted progress of its pipeline.
As a result, Apollomics believes that its current capital resources will fund planned operations through the first quarter of 2025.
Dr. Plunkett brings to Apollomics over 25 years of strategic and financial experience within the biopharmaceutical sector, including extensive fundraising and corporate development expertise.
In March 2023, the Company raised $23.7 million in a private placement in public equity (PIPE) financing, before transaction expenses.

NextGen MedStaff Revolutionizes Traveling Nurse Staffing, Paving the Way for Unprecedented Earnings. "Will Present This Week at GCN Investor Conference, Newport Beach."

Retrieved on:

Tuesday, March 19, 2024

Conference, Communication, Travel, AI, ITunes, GCN, Nursing, Nextgen

By eliminating the traditional recruiter middleman, NextGen MedStaff has empowered healthcare professionals to achieve earnings far beyond industry norms.

Key Points:

By eliminating the traditional recruiter middleman, NextGen MedStaff has empowered healthcare professionals to achieve earnings far beyond industry norms.
Mark your calendars for March 21, 2024, as NextGen MedStaff takes center stage at the Marriott Renaissance Newport Beach during the GCN Investor Conference.
From its inception, NextGen MedStaff set out to redefine the staffing agency paradigm, pioneering the concept of a true recruiter-less approach.
With this infusion of capital, NextGen MedStaff aims to expedite development initiatives, AI Learning app development, boost brand awareness, and capture additional market share.

GeeTest Introduces Device Fingerprinting, a front-line defence mechanism that effectively combats evolving cyber threats

Retrieved on:

Friday, March 1, 2024

Knowledge, Device, Algorithm, Risk management, IDS, GCN

WUHAN, China, March 1, 2024 /PRNewswire/ -- GeeTest , a leader in innovative bot management solutions, proudly presents its latest offering – GeeTest Device Fingerprinting.

Key Points:

WUHAN, China, March 1, 2024 /PRNewswire/ -- GeeTest , a leader in innovative bot management solutions, proudly presents its latest offering – GeeTest Device Fingerprinting.
GeeTest Device Fingerprinting steps in as a proactive and advanced solution to bridge this gap.
GeeTest Device Fingerprinting leverages cutting-edge technologies such as Triple-Dimensional Review Technology, GCN Knowledge Graph, and Weak Feature Identification Technology.
By intelligently identifying and tracking devices, it offers a robust defense mechanism against a multitude of threats faced by industries today.

Apollomics Presents Interim Data from Two Ongoing Phase 2 Clinical Trials with Vebreltinib in NSCLC Patients with MetExon14 Skipping Mutation

Retrieved on:

Monday, December 4, 2023

MET, Conference, APLM, Lung cancer, NACLC, GCN, Patient, Safety, NSCLC, Antibiotics

FOSTER CITY, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced the presentation of vebreltinib efficacy and safety data from the ongoing multi-cohort Phase 2 KUNPENG trial (NCT04258033) and the ongoing global multi-cohort Phase 2 SPARTA trial (NCT03175224) at the 2023 IASLC North America Conference on Lung Cancer (NACLC), that was held December 1-3, 2023, in Chicago, Illinois.

Key Points:

Vebreltinib appears efficacious in non-small cell lung cancer (NSCLC) patients with MetExon14 skipping mutation with or without co-occurring MET amplification.
Of the 83 NSCLC patients with MetExon14 skipping mutation with available gene copy number (GCN) data from the Phase 2 KUNPENG and SPARTA trials, 91.6% did not have co-occurring MET amplifications, reflecting the real-world distribution of the NSCLC patients with MetExon14 skipping mutation from two large public databases (83.6% and 91.9%)1.
“For the first time, we report the ORR of vebreltinib by GCN in NSCLC patients with MetExon14 skipping mutation.
Of NSCLC patients with MetExon14 skipping mutation with available GCN data included in this analysis, 91.6% had no co-occurring MET amplification (GCN

Genome Insight to Unveil Hong Kong Real-World Evidence on Target Enhanced Whole Genome Sequencing at 2023 AACR-KCA Joint Conference

Retrieved on:

Friday, November 17, 2023

Genome Insight, a precision healthcare solutions company advancing whole-genome technology for accurate diagnosis and personalized treatment for cancer and rare disease, will announce new-real-world evidence from Hong Kong on the application of Target Enhanced Whole Genome Sequencing (TE-WGS) at the 2023 AACR-KCA joint conference on Precision Medicine in Cancer in Seoul, Korea.

Key Points:

Genome Insight, a precision healthcare solutions company advancing whole-genome technology for accurate diagnosis and personalized treatment for cancer and rare disease, will announce new-real-world evidence from Hong Kong on the application of Target Enhanced Whole Genome Sequencing (TE-WGS) at the 2023 AACR-KCA joint conference on Precision Medicine in Cancer in Seoul, Korea.
(Photo: Business Wire)
Genome Insight's presentation will feature the outcomes of a collaborative real-world evidence program on TE-WGS in lung cancers.
Genome Insight will present the case of a 78-year-old Asian man from Hong Kong with poorly differentiated Non-Small Cell Lung Cancer (NSCLC).
"We are thrilled to present this real-world evidence from Hong Kong at the esteemed 2023 AACR-KCA Joint Conference," said Ryul Kim, Chief Technology Officer.

WiMi Announced Multi-Level Feature Fusion Algorithm Based on Convolutional Neural Networks

Retrieved on:

Tuesday, November 21, 2023

Cloud, WIMI, GCN, Classification, Holography, RNN, Learning, Natural language processing, Research, Augmented reality, CNN, Algorithm, 3D printing

The multilevel feature fusion algorithm studied by WiMi adopts a deep network structure, and gradually extracts the high-level features of the image through multiple convolutional and pooling operations, to better express the semantic information of the image.

Key Points:

The multilevel feature fusion algorithm studied by WiMi adopts a deep network structure, and gradually extracts the high-level features of the image through multiple convolutional and pooling operations, to better express the semantic information of the image.
The multi-level feature fusion algorithm, as an improved CNN model, has important applications in the field of image processing.
The current multi-level feature fusion algorithm mainly focuses on the fusion of shallow and mid-level features, and in the future, WiMi will further explore deeper feature fusion, such as the fusion of higher-level features, to improve the algorithm's performance and expressive ability.
The attention mechanism is introduced into the multilevel feature fusion algorithm to improve the network's ability to perceive and utilize key features.

Nintendo Download: Your Letter Has Arrived!

Retrieved on:

Thursday, November 9, 2023

(Graphic: Business Wire)

Key Points:

(Graphic: Business Wire)
Hogwarts Legacy – Your letter from Hogwarts arrives on Nov. 14.
Pre-orders are available now in Nintendo eShop and in the My Nintendo Store on Nintendo.com.
Stick to the Course – A new My Nintendo reward is cruising your way: Mario Kart 8 Deluxe Vinyl Sticker Sheet No.
Nintendo eShop sales on Nintendo Switch:
Also new this week in Nintendo eShop on Nintendo Switch:

Fans to Meet World’s Best Riders Face-to-Face With the Launch of the First-ever Track Cycling Metaverse Experience

Retrieved on:

Wednesday, November 8, 2023

Discovery Sports Europe, the metaverse experience utilises Web3 technology to bring a wealth of on-demand content to fans worldwide.

Key Points:

Discovery Sports Europe, the metaverse experience utilises Web3 technology to bring a wealth of on-demand content to fans worldwide.
It will provide an innovative way for new and existing audiences to deepen their understanding of track cycling and its athletes.
Fans can take part by downloading the UCI Track Champions League-Verse from the Apple App Store to complete a simple free registration process.
Fans can catch up on all the action from Rounds 1 and 2 and learn more by visiting ucitrackchampionsleague.com .

Powered by Its Industry-Leading Comprehensive Multi-Omic Database, Caris Life Sciences to Showcase Research at ESMO 2023

Retrieved on:

Tuesday, October 17, 2023

IRVING, Texas, Oct. 17, 2023 /PRNewswire/ -- Caris Life Sciences®(Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular science and AI, today announced that the company and collaborators within the Caris Precision Oncology Alliance™ (POA) will collectively present seven studies across a breadth of tumor types at the European Society for Medical Oncology (ESMO) Congress 2023 in Madrid, Spain from October 20-24, 2023 (Booth #513). The findings demonstrate the power of Caris' comprehensive clinico-genomic database that enable novel insights into cancer that could have profound effects on a patient's diagnosis, prognosis, care plan and response to treatment.

Key Points:

The findings demonstrate the power of Caris' comprehensive clinico-genomic database that enable novel insights into cancer that could have profound effects on a patient's diagnosis, prognosis, care plan and response to treatment.
"The research being presented at this year's ESMO Congress is a testament to Caris' continued commitment to data-driven molecular innovation and large-scale collaboration to answer some of the pressing questions in precision oncology today," said Chadi Nabhan , M.D., MBA, FACP, Chairman of the Caris POA.
"The findings of these studies illustrate the power of comprehensive molecular profiling to identify underlying tumor biology setting the stage for therapeutics that improve patient outcomes.
Alongside our POA partners, we are pioneering new approaches to help deliver the right treatments to the right patients at the right time."

Qples by Fobi Announces Annual Contract Renewal with Marketing Solutions Leader Vericast

Retrieved on:

Thursday, June 22, 2023

Kingsley Fobi, CPG, GCN, Public key certificate, AI, Cryptocurrency, Online shopping, Compost

VANCOUVER, BC, June 22, 2023 (GLOBE NEWSWIRE) -- Fobi AI Inc. (FOBI:TSXV) (FOBIF:OTCQB) (the "Company" or "Fobi"), an industry leader in harnessing AI and data intelligence to enable digital transformation, is pleased to announce that the Company’s subsidiary, Qples by Fobi, has renewed its annual contract agreement with leading marketing solutions provider, Vericast.

Key Points:

VANCOUVER, BC, June 22, 2023 (GLOBE NEWSWIRE) -- Fobi AI Inc. (FOBI:TSXV) (FOBIF:OTCQB) (the "Company" or "Fobi"), an industry leader in harnessing AI and data intelligence to enable digital transformation, is pleased to announce that the Company’s subsidiary, Qples by Fobi, has renewed its annual contract agreement with leading marketing solutions provider, Vericast.
Fobi will generate revenue from this agreement through an annual licensing fee as well as per campaign and per coupon fees.
Vericast is the first marketing solutions company to launch a Universal Coupon solution with store-level redemption insights, precise consumer targeting, and scalable reach.
Eddy Watson, President of Qples by Fobi, stated: “This contract renewal with Vericast is a big win for Qples.